Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 022545

Expand all

TEKAMLO (ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE)
EQ 150MG BASE;EQ 5MG BASE Marketing Status: Discontinued

Active Ingredient: ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
Proprietary Name: TEKAMLO
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 150MG BASE;EQ 5MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N022545
Product Number: 001
Approval Date: Aug 26, 2010
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

TEKAMLO (ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE)
EQ 150MG BASE;EQ 10MG BASE Marketing Status: Discontinued

Active Ingredient: ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
Proprietary Name: TEKAMLO
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 150MG BASE;EQ 10MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N022545
Product Number: 002
Approval Date: Aug 26, 2010
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

TEKAMLO (ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE)
EQ 300MG BASE;EQ 5MG BASE Marketing Status: Discontinued

Active Ingredient: ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
Proprietary Name: TEKAMLO
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 300MG BASE;EQ 5MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N022545
Product Number: 003
Approval Date: Aug 26, 2010
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

TEKAMLO (ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE)
EQ 300MG BASE;EQ 10MG BASE Marketing Status: Discontinued

Active Ingredient: ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
Proprietary Name: TEKAMLO
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 300MG BASE;EQ 10MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N022545
Product Number: 004
Approval Date: Aug 26, 2010
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English